Roche's Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma
CompanyDrug

Roche’s Lunsumio SC Wins EU Conditional Approval for Follicular Lymphoma

Roche's giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial
CompanyDrug

Roche’s giredestrant SERD Achieves iDFS Win in Phase 3 lidERA Breast Cancer Trial

Hengrui's HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial
CompanyDrug

Hengrui’s HRS-6209 CDK4 Inhibitor Wins NMPA Nod for Breast Cancer Combo Trial

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic
CompanyDeals

Gate Bioscience Closes $65M Series B to Advance Molecular Gates to Clinic

Hengrui's HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials
CompanyDrug

Hengrui’s HRS-4642 KRAS G12D Inhibitor Wins NMPA Nod for Phase 1b/2 Solid Tumor Trials

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First
Company

Takeda Launches TCIC Digital Healthcare Innovation Center in Chengdu, a China‑First

BeOne's Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial
CompanyDrug

BeOne’s Zanidatamab Achieves PFS & OS Wins in HERIZON-GEA-01 Phase 3 HER2-Positive Cancer Trial

Biokin's iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First
CompanyDrug

Biokin’s iza-bren ADC Achieves Dual PFS & OS Endpoints in Phase 3 Esophageal Cancer, a Global First

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy
CompanyDeals

Resight Therapeutics Secures Tens‑Millions RMB Angel Round to Accelerate iPSC‑Derived Corneal Endothelial Cell Therapy

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients
CompanyDrug

BMS and J&J Halt Phase III Milvexian Anticoagulant Trial for Acute Coronary Syndrome Patients

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients
CompanyDrug

Jiangsu Hengrui Secures NMPA Approval for Tegileridine in Mechanically Ventilated ICU Patients

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915
CompanyDeals

Johnson & Johnson to Acquire Halda Therapeutics for $3.05 B – Deal Highlights First‑in‑Class Oral RIPTAC HLD‑0915